• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How GE HealthCare’s New Intraoperative Ultrasound–Navigation Integration Could Shape GEHC Investors’ View of Imaging

    Simply Wall St·04/12/2026 00:36:46
    Listen to the news
    • GE HealthCare recently announced that its bkActiv intraoperative ultrasound system is now digitally integrated with Medtronic’s FDA-cleared Stealth AXiS surgical navigation platform, enabling real-time imaging during cranial procedures in operating rooms across the United States.
    • This plug-and-play link between intraoperative ultrasound and navigation workflows gives neurosurgeons a way to address “brain shift” by viewing live ultrasound alongside pre-operative MRI or CT scans without disrupting existing surgical routines.
    • Next, we’ll explore how this new bkActiv–Stealth AXiS integration shapes GE HealthCare’s investment narrative, especially around advanced intraoperative imaging.

    Outshine the giants: these 21 early-stage AI stocks could fund your retirement.

    GE HealthCare Technologies Investment Narrative Recap

    To own GE HealthCare, you need to believe in its ability to keep growing its installed base and deepen its role inside operating rooms and imaging suites through differentiated technology and partnerships. The bkActiv–Stealth AXiS integration reinforces that story in neurosurgery, but it does not materially change the near term focus on executing its broader product pipeline and managing tariff and China related pressures, which remain key risks to margins and cash flow.

    Among recent developments, the Photonova Spectra photon counting CT system with FDA 510(k) clearance stands out alongside bkActiv as part of GE HealthCare’s push into higher end imaging. Together, these kinds of launches support the catalyst of expanding advanced modalities and related software, which could be important if competition in medical imaging tightens and customers become more selective about capital spending.

    Yet behind the promise of smarter operating rooms, investors still need to consider the risk that competitor product advances could...

    Read the full narrative on GE HealthCare Technologies (it's free!)

    GE HealthCare Technologies' narrative projects $23.7 billion revenue and $2.7 billion earnings by 2029. This requires 4.8% yearly revenue growth and a roughly $0.6 billion earnings increase from $2.1 billion today.

    Uncover how GE HealthCare Technologies' forecasts yield a $91.74 fair value, a 25% upside to its current price.

    Exploring Other Perspectives

    GEHC 1-Year Stock Price Chart
    GEHC 1-Year Stock Price Chart

    Three fair value estimates from the Simply Wall St Community cluster between US$91.74 and US$110.87, highlighting how differently individual investors view GE HealthCare’s upside. You should weigh those views against the catalyst of new advanced imaging integrations and the opposing risk of rival product pipelines affecting the company’s ability to sustain its position.

    Explore 3 other fair value estimates on GE HealthCare Technologies - why the stock might be worth as much as 52% more than the current price!

    Reach Your Own Conclusion

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Curious About Other Options?

    Our daily scans reveal stocks with breakout potential. Don't miss this chance:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.